CLNN Stock Summary and Trading Ideas (Clene | NASDAQ:CLNN)

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

Clene trades on the NASDAQ stock market under the symbol CLNN.

As of March 4, 2025, CLNN stock price declined to $4.26 with 32,017 million shares trading.

CLNN has a beta of 0.55, meaning it tends to be less sensitive to market movements. CLNN has a correlation of 0.01 to the broad based SPY ETF.

CLNN has a market cap of $35.47 million. This is considered a Sub-Micro Cap stock.

Last quarter Clene reported $87,000 in Revenue and -$1.22 earnings per share. This fell short of revenue expectation by $-3,000 and exceeded earnings estimates by $.10.

In the last 3 years, CLNN traded as high as $102.60 and as low as $3.82.

The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF.

CLNN has underperformed the market in the last year with a price return of -45.2% while the SPY ETF gained +13.9%. However, in the short term, CLNN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.6% vs -4.2% return in SPY. But in the last 2 weeks, CLNN shares have been beat by the market, returning -11.4% compared to an SPY return of -5.4%.

CLNN support price is $4.11 and resistance is $4.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.